HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Thromboxane-A Synthase

Subscribe to New Research on Thromboxane-A Synthase

An enzyme found predominantly in platelet microsomes. It catalyzes the conversion of PGG(2) and PGH(2) (prostaglandin endoperoxides) to thromboxane A2. EC 5.3.99.5.

Also Known As:

Thromboxane A Synthase; Thromboxane A2 Synthetase; A2 Synthetase, Thromboxane; Synthase, Thromboxane A; Synthase, Thromboxane-A; Synthetase, Thromboxane; Synthetase, Thromboxane A2; Thromboxane Synthetase; (5Z,13E)-(15S)-9alpha,11alpha-Epidioxy-15-hydroxyprosta-5,13-dienoate thromboxane-A(2)-isomerase

Networked: 309 relevant articles (22 outcomes, 36 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 25709
  - Isomerases: 18
    - Intramolecular Oxidoreductases
      - Thromboxane-A Synthase: 309
        RS 86328

Experts

1.	Sung, Ki Bum: 1 article (04/2009)
2.	Shin, Hyoung Doo: 1 article (04/2009)
3.	Park, Sun Ah: 1 article (04/2009)
4.	Park, Jeong Ho: 1 article (04/2009)
5.	Park, Choon-Sik: 1 article (04/2009)
6.	Park, Byung Lae: 1 article (04/2009)
7.	Lee, You Kyoung: 1 article (04/2009)
8.	Lee, Tae Kyeong: 1 article (04/2009)
9.	Chang, Hun Soo: 1 article (04/2009)
10.	Sato, Yoshinori: 1 article (07/2004)

Related Diseases

1.	Ischemia 07/01/1996 - "Thromboxane synthetase inhibitor ameliorates delayed neuronal death in the CA1 subfield of the hippocampus after transient global ischemia in gerbils." 01/01/1986 - "This study was performed to examine potential protective effects of UK 38.485, an inhibitor of thromboxane synthetase, in canine myocardium stressed by transient ischemia. " 01/01/1987 - "Protective effects of selective inhibitor of thromboxane synthetase (OKY-046) and thromboxane antagonist (ONO-3708) on ischemia-induced mitochondrial dysfunction in canine heart." 04/01/1988 - "Platelets are suggested to exacerbate ischemia-induced myocardial injury, which has led to the study of various antiplatelet therapies including thromboxane synthetase inhibitors (TXSI). " 02/01/1999 - "The anti-thromboxane A2 synthetase activity of myocardial tissue and its variation during ischemia and reperfusion in isolated rabbit heart." Order ALL the reference details at left...
2.	Septic Shock (Toxic Shock Syndrome) 06/01/1997 - "Protective effects of a thromboxane synthetase inhibitor and continuous arteriovenous hemofiltration in rat endotoxic shock." 06/01/1980 - "Protective effects of thromboxane synthetase inhibitors in rats in endotoxic shock." 05/01/1986 - "Improvement in organ blood flow by inhibition of thromboxane synthetase during experimental endotoxic shock in the rat." 01/01/1983 - "Thromboxane synthetase inhibitors in septic shock." 04/01/1983 - "Effects of a pyridine derivative thromboxane synthetase inhibitor and its inactive isomer in endotoxic shock in the rat." Order ALL the reference details at left...
3.	Shock 06/01/1983 - "Protective effects of thromboxane A2 synthetase inhibitors on endotoxin shock." 09/01/1987 - "In some shock models, however, results with thromboxane synthetase inhibitors have been conflicting. " 01/01/1988 - "Both 150 and 300 mg/kg doses of picotamide significantly (P less than 0.05) improved survival in endotoxin shock at 48 hr. These studies demonstrate that picotamide is a selective thromboxane synthetase inhibitor, and that it may be useful during disease states characterized by increased TxA2 synthesis." 02/15/1990 - "Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits." 06/15/1983 - "The effect of cyclo-oxygenase and thromboxane synthetase inhibitors on shock induced by injection of heterologous blood in cats." Order ALL the reference details at left...
4.	Glomerulonephritis 03/01/1992 - "Thromboxane synthetase inhibitors have been used successfully to treat experimentally induced glomerulonephritis in several species and this treatment appears to hold promise for naturally occurring glomerulonephritis in dogs." 10/01/1986 - "Effect of a thromboxane synthetase inhibitor on eicosanoid synthesis and glomerular injury during acute unilateral glomerulonephritis in the rat." 05/01/1992 - "Effects of a thromboxane synthetase inhibitor on established immune complex glomerulonephritis in dogs." 03/01/1991 - "Effects of thromboxane synthetase inhibition on immune complex glomerulonephritis." 10/01/1988 - "Effects of a specific thromboxane synthetase inhibitor on development of experimental Dirofilaria immitis immune complex glomerulonephritis in the dog." Order ALL the reference details at left...
5.	Endotoxemia 11/01/1990 - "The effect of thromboxane synthetase inhibition on cardiopulmonary function during endotoxemia in sheep." 04/01/1985 - "The thromboxane synthetase inhibitor dazoxiben has improved survival and decreased pulmonary hypertension in experimental endotoxemia. " 06/01/1997 - "We determined the efficacy of continuous arteriovenous hemofiltration (CAVH) and a thromboxane synthetase inhibitor (TSI) on survival and their effect on TXA2, PGI2, TNF alpha, and IL-1beta production in rat endotoxemia. " 01/01/1986 - "Two cyclooxygenase inhibitors (flunixin meglumine and phenylbutazone) and a selective thromboxane synthetase inhibitor were assessed in the management of experimental equine endotoxemia. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	dazoxiben
3.	Thromboxane A2 (A2, Thromboxane)
4.	dazmegrel
5.	Thromboxane Receptors (Thromboxane Receptor)
6.	Aspirin (Acetylsalicylic Acid)
7.	ozagrel
8.	picotamide
9.	Lipoxygenase (Lipoxygenase-1)
10.	Prostaglandin H2 Thromboxane A2 Receptors

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Chemoprevention
3.	Homologous Transplantation (Allograft)
4.	Intramuscular Injections
5.	Intravenous Infusions

blog comments powered by Disqus

TREATMENT OPTIONS
for Ischemia,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 2957 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>